OncoMatch/Clinical Trials/NCT06835569
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Is NCT06835569 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including ALTA3263 and cetuximab for cancer.
Treatment: ALTA3263 · cetuximab — The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care therapy — appropriate to tumor type and stage
Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
Cannot have received: KRAS inhibitor
Exception: certain exceptions are described in the full study protocol
Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Orlando, Florida
- Research Site · Boston, Massachusetts
- Research Site · Boston, Massachusetts
- Research Site · New York, New York
- Research Site · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06835569 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify